NR1H4 and cholestasis: The activation of FXR inhibits the synthesis of BAs in hepatocytes, increases the efflux of BAs from hepatocytes, thereby reducing the exposure of hepatocytes to BAs, and has become a key therapeutic target for cholestasis [122].